Astria delivered on all of its objectives for STAR-0310, an OX40 antibody, in a Phase 1 trial, Cantor Fitzgerald tells investors in a research note. The analyst, who has an Overweight rating and $49 price target on the shares, says Astria rationally engineered out T cell depletion to avoid fever and chills, but retained anti-inflammatory efficacy preclinically, widening the therapeutic window.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics announces initial results from STAR-0310 trial
- Promising Developments and Financial Stability Drive Buy Rating for Astria Therapeutics
- Astria Therapeutics price target raised to $26 from $25 at Citizens JMP
- Strong Financial Position and Strategic Partnerships Drive Buy Rating for Astria Therapeutics
- Astria Therapeutics Reports Increased Losses Amid R&D Expansion